We also conducted survival analysis in patients with different clinical stages (Fig. S1A and B) and pathological grades (Fig. S1C and D), and found that regardless of early or late stage, high or low differentiation, CRABP2 was a risk factor for OS and PFS in ovarian cancer patients. This evidence concerns the gene CRABP2 and ovarian cancer.